EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Euglycemic ketoacidosis in a non-diabetic patient with Duchenne muscular dystrophy on dapagliflozin

Ana María Gutiérrez-Baena iD, Mariona Tegido Mateu, Paula Álvarez Schlegel, Sandra Clotet-Vidal iD

Internal and Emergency Medicine · 2025-09 · 20 (6) · 1865-1867

DOI: 10.1007/s11739-025-04058-3 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Internal and Emergency Medicine, online erschienen am 01.09.2025. Verfasst von Ana María Gutiérrez-Baena und 3 weiteren Autor:innen. Beteiligte Einrichtung: Internal Medicine Department, Hospital de La Santa Creu i Sant Pau, 08041, Barcelona, Spain. agutierrezba@santpau.cat. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Muscular Dystrophy, Duchenne, Glucosides, Ketosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Euglycemic ketoacidosis (EKA) is an uncommon but potentially life-threatening condition characterized by ketoacidosis with normal or mildly elevated blood glucose levels. We report the case of a 24-year-old male with advanced Duchenne muscular dystrophy and cardiomyopathy treated with dapagliflozin, who developed EKA triggered by reduced food intake due to dysphagia and delayed intestinal motility. The patient presented with metabolic acidosis and elevated ketones but maintained normal glucose levels. Discontinuation of dapagliflozin, along with intravenous bicarbonate and dextrose administration, led to clinical and biochemical resolution without the need for insulin therapy. This case highlights the importance of recognizing SGLT2 inhibitor-associated EKA in non-diabetic patients, especially during fasting or stress conditions, to prevent misdiagnosis and ensure prompt management. Increased clinical vigilance and patient education are essential given the expanding use of these agents in non-diabetic populations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsMuscular Dystrophy, DuchenneGlucosidesKetosisHumansMaleYoung AdultSodium-Glucose Transporter 2 Inhibitors

Stichwörter der Autor:innen

DapaglifozinEuglycemic ketoacidosisNon-diabetic

Substanzen

Benzhydryl CompoundsdapagliflozinGlucosidesSodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Internal Medicine Department, Hospital de La Santa Creu i Sant Pau, 08041, Barcelona, Spain. agutierrezba@santpau.cat.
  • Institut Català de La Salut, CAP Besòs, 08019, Barcelona, Spain.
  • Internal Medicine Department, Hospital de La Santa Creu i Sant Pau, 08041, Barcelona, Spain.

ORCID-Profile: Ana María Gutiérrez-Baena, Sandra Clotet-Vidal

Zitieren

APA

Gutiérrez-Baena, A. M., Tegido Mateu, M., Álvarez Schlegel, P., & Clotet-Vidal, S. (2025). Euglycemic ketoacidosis in a non-diabetic patient with Duchenne muscular dystrophy on dapagliflozin. Internal and Emergency Medicine, 20(6), 1865-1867. https://doi.org/10.1007/s11739-025-04058-3

Vancouver

Gutiérrez-Baena AM, Tegido Mateu M, Álvarez Schlegel P, Clotet-Vidal S. Euglycemic ketoacidosis in a non-diabetic patient with Duchenne muscular dystrophy on dapagliflozin. Internal and Emergency Medicine. 2025;20(6):1865-1867. doi:10.1007/s11739-025-04058-3

BibTeX
@article{GutirrezBaena2025,
  author = {Gutiérrez-Baena, Ana María and Tegido Mateu, Mariona and Álvarez Schlegel, Paula and Clotet-Vidal, Sandra},
  title = {Euglycemic ketoacidosis in a non-diabetic patient with Duchenne muscular dystrophy on dapagliflozin},
  journal = {Internal and Emergency Medicine},
  year = {2025},
  volume = {20},
  number = {6},
  pages = {1865--1867},
  doi = {10.1007/s11739-025-04058-3}
}
Kostenlos starten →